As an example, pembrolizumab, an anti-PD-L1 antibody, is currently approved for first-line in patients whose tumors express ≥50% of PD-L1 and for second-line use in NSCLC patients whose tumors express at least 1% of PD-L1 without ALK or EGFR alterations [16]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.